Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer

Pinto, Mauricio P.; Balmaceda, Catalina; Bravo, María Loreto; Kato, Sumie; Villarroel, Alejandra; Owen, Gareth I.; Roa, Juan Carlos; Cuello, Mauricio; Ibáñez, Carolina

doi:10.1016/j.ygyno.2018.07.025

Cited by 83 publications

(90 citation statements)

References 40 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most abundant type of lymphocyte subset is the T cell. Several studies have shown a positive prognostic impact of a high concentration of tumor-infiltrating T cells in various malignancies, including ovarian cancer [12][13][14][15][16][17][18][19][20][21].…”

Section: Introductionmentioning

confidence: 99%

Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy

et al. 2020

View full text Add to dashboard Cite

Purpose: Biomarkers are needed to guide treatment decisions in recurrent ovarian cancer, as a high proportion of patients do not benefit from treatments. Data on immune subsets in patients receiving chemotherapy are scarce. We investigated the impact of T cells, B cells, neutrophils and the neutrophil-lymphocyte ratio (NLR) in ovarian cancer patients receiving palliative chemotherapy. Methods: Blood samples were collected prospectively at baseline in recurrent ovarian cancer (N = 72) receiving chemotherapy. T cells, B cells, neutrophils, and NLR were analyzed. Primary and secondary endpoints were overall survival (OS) and treatment response, respectively. Cutoffs for T and B cells were predefined. Results: In patients with low vs. high T and B cells counts, OS was 6.1 months vs 12.0 months (P = 0.017) and 6.1 months vs 12.0 months (P = 0.011, respectively. Low T and B cells analyzed as continuous variables were also associated with unfavorable OS, P = 0.011 and P = 0.007, respectively. Neutrophils had no significant prognostic impact. Median NLR was 4.1. High vs. low NLR was associated with poor survival, 7.4 months vs. 15.9 months (P = 0.012). In multivariate analysis including platinum sensitivity, number of prior lines of chemotherapy, and performance status, high NLR remained an independent poor prognostic factor HR: 2.17 (95% CI 1.21-3.88) (P = 0.009). High NLR was also significantly associated with lack of response, OR 0.15 (95% CI: 0.04-0.51) (P = 0.002). Conclusion: In recurrent ovarian cancer patients undergoing palliative chemotherapy, low T and B lymphocyte counts had an unfavorable prognostic impact. High NLR was associated with lack of response and a poor prognosis, and the parameter may be used in patient counselling and treatment decisions.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Furthermore, several reports indicated that the efficacy of PD-1 inhibitors might be related to peripheral blood lymphocytes. Inflammatory markers such as neutrophil-tolymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) may be potential predictive and prognostic factors related to immunotherapy, as shown in recent studies (33)(34)(35). The NLR/PLR was defined as an absolute neutrophil/platelet count divided by an absolute lymphocyte count.…”

Section: Discussionmentioning

confidence: 99%

Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Negative Patient With Refractory Metastatic Esophageal Squamous Cell Carcinoma: A Case Report and Literature Review

2020

View full text Add to dashboard Cite

Esophageal squamous cell carcinoma (ESCC) is a malignancy with poor prognosis, which is often diagnosed at a late stage. Effective treatment options are limited when patients fail standard systemic therapy. The application of PD-1 inhibitors have led to a paradigm shift in the treatment of ESCC, but its efficacy as monotherapy is limited. Previous studies have shown that the antitumor effects may be reinforced when a PD-1 inhibitor is combined with radiotherapy or GM-CSF. This study aimed to report a case of a patient about advanced unresectable ESCC negative expression of PD-L1, who experienced tumor progression after chemoradiotherapy and targeted therapy.A significant systemic effect was seen after PD-1 inhibitor combined with GM-CSF and stereotactic body radiotherapy (SBRT) for metastatic lesions, however, severe pneumonia occurred after the triple-combination therapy. This study also reviewed several reports about the efficacy and safety of combination therapy.

show abstract

“…A meta-analysis with almost 4500 patients with mixed or serous histologic subtypes of ovarian cancer showed that intraepithelial CD3+, CD8+, and CD103+ TILs are clearly associated with increased overall survival and disease specific survival, with the location of TILs within the tumour being important for this prognostic effect [ 7 ]. T-cell infiltration has been shown to be subtype dependent in ovarian cancer [ 92 , 93 , 94 ]. Several studies have found that activated CD4+ T or CD8+ T tumour infiltrating lymphocytes are associated with good overall survival in HGSOC [ 93 , 94 , 95 , 96 , 97 ].…”

Section: Tumour Microenvironment (Tme) Of Solid Cancers Including mentioning

confidence: 99%

“…T-cell infiltration has been shown to be subtype dependent in ovarian cancer [ 92 , 93 , 94 ]. Several studies have found that activated CD4+ T or CD8+ T tumour infiltrating lymphocytes are associated with good overall survival in HGSOC [ 93 , 94 , 95 , 96 , 97 ]. Different T-cell infiltration is prognostic for other epithelial ovarian cancer subtypes.…”

Section: Tumour Microenvironment (Tme) Of Solid Cancers Including mentioning

confidence: 99%

Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy

Macpherson

Barry

Ricciardelli

et al. 2020

JCM

View full text Add to dashboard Cite

Recent advances in the understanding of immune function and the interactions with tumour cells have led to the development of various cancer immunotherapies and strategies for specific cancer types. However, despite some stunning successes with some malignancies such as melanomas and lung cancer, most patients receive little or no benefit from immunotherapy, which has been attributed to the tumour microenvironment and immune evasion. Although the US Food and Drug Administration have approved immunotherapies for some cancers, to date, only the anti-angiogenic antibody bevacizumab is approved for the treatment of epithelial ovarian cancer. Immunotherapeutic strategies for ovarian cancer are still under development and being tested in numerous clinical trials. A detailed understanding of the interactions between cancer and the immune system is vital for optimisation of immunotherapies either alone or when combined with chemotherapy and other therapies. This article, in two main parts, provides an overview of: (1) components of the normal immune system and current knowledge regarding tumour immunology, biology and their interactions; (2) strategies, and targets, together with challenges and potential innovative approaches for cancer immunotherapy, with attention given to epithelial ovarian cancer.

show abstract

Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer

Cited by 83 publications

References 40 publications

Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy

Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy

Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Negative Patient With Refractory Metastatic Esophageal Squamous Cell Carcinoma: A Case Report and Literature Review

Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy

Contact Info

Product

Resources

About